Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 111 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Antibiotic Resistant Infection Clear all

Conditions: Bacteremia, Pseudomonas Infections
Interventions: Blood draws, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions: Arm 2: Decolonization; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 52
States / cities: West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more

Conditions: Urinary Tract Infection
Interventions: Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 10 Years
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Staphylococcal Skin Infections
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more

Conditions: Pneumonia, Methicillin-Resistant Staphylococcus Aureus
Interventions: Polymerase Chain Reaction (PCR); Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection, Adverse Effects
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions: vancomycin or gentamicin, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Childhood Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 60 Months
Enrollment: 190,238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions: Not listed
Lead sponsor: Connie Price; Other
Eligibility: 18 Years and older
Enrollment: 2,298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Denver, Colorado • Washington D.C., District of Columbia

Conditions: Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection, Immune Deficiency, Hypogammaglobulinemia, Septic Arthritis, Mycoplasma Hominis
Interventions: anti-mycoplasma hominis antibodies; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Gram-Negative Bacterial Infections
Interventions: IV antibiotic treatment from prior, differing IV antibiotic treatment; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: E Coli Infection
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions: Antibiotic; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 34
States / cities: Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more

Conditions: Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Mountain Home Research & Education Corporation; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Johnson City, Tennessee • Mountain Home, Tennessee

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: Exebacase, Placebo; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 12 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 55
States / cities: Birmingham, Alabama • Orange, California • Sacramento, California + 47 more

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: MRSA, VRE
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 19,856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Skin Diseases, Infectious
Interventions: Culture; Procedure
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Abscess
Interventions: Septra; Drug
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Bacterial Infections and Mycoses
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: Up to 18 Months
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diarrhea Travelers, Antibiotic Resistant Infection
Interventions: Bismuth subsalicylate, Placebo; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)

Active Bathing to Eliminate Infection (ABATE Infection) Trial

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

Trial of MRSA Polymerase Chain Reaction for Pneumonia

Towards Reducing Resistance and Hematological Toxicity of Linezolid

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

Mortality Reduction After Oral Azithromycin: Mortality Study

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

Personalized Immunotherapeutic for Antibiotic-resistant Infection

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

Antibiotic Resistant Community-Acquired E. Coli

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Benefits of Universal Glove and Gowning

Effective Antibiotic Treatment of MRSA

Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

Infant Antibiotic Resistance and Implications for Therapeutic Decision-making

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea